The rilzabrutinib FDA approval on August 29, 2025, introduced a groundbreaking therapy for patients struggling with immune thrombocytopenia (ITP) and other immune-mediated conditions. Marketed as Wayrilz, rilzabrutinib is a selective oral Bruton’s tyrosine kinase (BTK) inhibitor that brings new hope to patients who often face limited treatment options and chronic complications. This milestone approval is …
Introduction Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent swelling of various tissues, such as the face, limbs, abdomen, or airways. These attacks can be painful, disabling, and sometimes life-threatening (especially if the airways are involved). While conventional treatments have made great progress, many patients still face uncertainty and recurrent episodes. Enter …
Introduction The U.S. Food and Drug Administration (FDA) granted accelerated approval to Zongertinib (brand name Hernexeos) on August 8, 2025, marking a significant milestone in lung cancer treatment. Zongertinib is approved for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and …
Introduction Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Accurate diagnosis and staging are crucial for choosing the right treatment plan and improving patient outcomes. Conventional imaging methods often fall short of detecting small or early lesions, especially in cases of recurrence. This is where Gozellix® comes in. After radiolabeling …
Bone health is one of the most important aspects of cancer treatment, especially for people whose disease has spread to the skeleton. Older cancer patients often face painful and dangerous bone complications, such as fractures, spinal cord compression, and bone lesions that require radiation or surgery. Bomyntra is a newly approved treatment designed to prevent …
Vision loss is one of the biggest life-changing problems for any individual. In March 2025, the approval of the Encelto implant brought new hope to patients with idiopathic macular telangiectasia type 2 (MacTel type 2). This allogeneic encapsulated cell-based gene therapy is designed to preserve vision in adults at risk of progressive vision loss due …
Introduction Millions of people worldwide suffer from asthma, and severe and persistent allergic asthma is difficult to control with standard treatments. On March 7, 2025, the US Food and Drug Administration (FDA) approved Omlyclo® (omalizumab) as the first interchangeable biosimilar for Xolair® (omalizumab). This approval is a significant milestone in respiratory medicine, increasing access to …
Introduction On February 14, 2025, the US Food and Drug Administration (FDA) approved vimseltinib, marketed under the brand name Romvimza™, for the treatment of tenosynovial giant cell tumor (TGCT) in adult patients. This is a significant advance for patients struggling with this rare, debilitating joint condition. Known as a switch-control kinase inhibitor of the colony-stimulating …
Introduction On February 11, 2025, the U.S. Food and Drug Administration (FDA) announced the approval of mirdametinib, marketed under the brand name Gomecli. This approval marks a historic milestone in the management of neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibromas (PNs) – a rare and challenging condition. The mirdametinib FDA approval is a significant advancement …
Introduction The field of biotechnology is constantly evolving, bringing new treatment options to conditions that were once considered difficult to manage. Among these innovations, clesrovimab-cfor, marketed under the brand name Enflonsia, has emerged as a promising monoclonal antibody therapy. Designed with advanced biotechnology, clesrovimab is gaining attention in the clinical practice and research communities for …
